Search research articles
Contact Us
Filters
Showing results (21-30 of 52) with videos related to
Page
of 6
Sort By:
The Journal of Urology
|
January 30, 2019
Confirmatory Magnetic Resonance Imaging with or without Biopsy Impacts Decision Making in Newly Diagnosed Favorable Risk Prostate Cancer
Kevin B Ginsburg, Rohith Arcot, Ji Qi, et al.
The Journal of Surgical Research
|
January 30, 2019
Variation in Physician-Specific Episode Payments for Major Cancer Surgery and Implications for the Merit-Based Incentive Program
Deborah R Kaye, Rodney L Dunn, Jonathan Li, et al.
Cancer
|
July 1, 2017
Understanding the relationship between the Centers for Medicare and Medicaid Services' Hospital Compare star rating, surgical case volume, and short-term outcomes after major cancer surgery
Deborah R Kaye, Edward C Norton, Chad Ellimoottil, et al.
Urology Practice
|
April 27, 2023
Association of Rural Hospital for-Profit Status With Higher Publicly Reported Prices for the Components of Inpatient Hematuria Evaluation Among Commercially Insured Patients
Ian Berger, Vishnukamal Golla, Marcelo Cerullo, et al.
JCO Oncology Practice
|
February 19, 2020
Association Between Delivery System Structure and Intensity of End-of-Life Cancer Care
Lindsey A Herrel, Ziwei Zhu, Jennifer J Griggs, et al.
Annals of Surgery
|
January 3, 2019
Understanding the Costs Associated With Surgical Care Delivery in the Medicare Population
Deborah R Kaye, Amy N Luckenbaugh, Mary Oerline, et al.
The American Journal of Managed Care
|
September 20, 2024
Systemic treatments for advanced prostate cancer: relationship between health insurance plan and treatment costs
Deborah R Kaye, Hui-Jie Lee, Alexander Gordee, et al.
Journal of Medical Economics
|
January 11, 2024
Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation
Deborah R Kaye, Ibrahim Khilfeh, Erik Muser, et al.
JCO Oncology Practice
|
January 23, 2023
Medication Payments by Insurers and Patients for the Treatment of Metastatic Castrate-Resistant Prostate Cancer
Deborah R Kaye, Hui-Jie Lee, Alexander Gordee, et al.
Urologic Oncology
|
April 4, 2026
Outcomes of Consolidative Surgery Following Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Cancer: A Real-World Experience
Alireza Ghoreifi, Christopher J Hoimes, Sundhar Ramalingam, et al.
Page
of 6
Search research articles
Search
Showing results (21-30 of 52) with videos related to
Sort By:
Page
of 6
The Journal of Urology
|
January 30, 2019
Confirmatory Magnetic Resonance Imaging with or without Biopsy Impacts Decision Making in Newly Diagnosed Favorable Risk Prostate Cancer
Kevin B Ginsburg, Rohith Arcot, Ji Qi, et al.
The Journal of Surgical Research
|
January 30, 2019
Variation in Physician-Specific Episode Payments for Major Cancer Surgery and Implications for the Merit-Based Incentive Program
Deborah R Kaye, Rodney L Dunn, Jonathan Li, et al.
Cancer
|
July 1, 2017
Understanding the relationship between the Centers for Medicare and Medicaid Services' Hospital Compare star rating, surgical case volume, and short-term outcomes after major cancer surgery
Deborah R Kaye, Edward C Norton, Chad Ellimoottil, et al.
Urology Practice
|
April 27, 2023
Association of Rural Hospital for-Profit Status With Higher Publicly Reported Prices for the Components of Inpatient Hematuria Evaluation Among Commercially Insured Patients
Ian Berger, Vishnukamal Golla, Marcelo Cerullo, et al.
JCO Oncology Practice
|
February 19, 2020
Association Between Delivery System Structure and Intensity of End-of-Life Cancer Care
Lindsey A Herrel, Ziwei Zhu, Jennifer J Griggs, et al.
Annals of Surgery
|
January 3, 2019
Understanding the Costs Associated With Surgical Care Delivery in the Medicare Population
Deborah R Kaye, Amy N Luckenbaugh, Mary Oerline, et al.
The American Journal of Managed Care
|
September 20, 2024
Systemic treatments for advanced prostate cancer: relationship between health insurance plan and treatment costs
Deborah R Kaye, Hui-Jie Lee, Alexander Gordee, et al.
Journal of Medical Economics
|
January 11, 2024
Real-world economic burden of metastatic castration-resistant prostate cancer before and after first-line therapy initiation
Deborah R Kaye, Ibrahim Khilfeh, Erik Muser, et al.
JCO Oncology Practice
|
January 23, 2023
Medication Payments by Insurers and Patients for the Treatment of Metastatic Castrate-Resistant Prostate Cancer
Deborah R Kaye, Hui-Jie Lee, Alexander Gordee, et al.
Urologic Oncology
|
April 4, 2026
Outcomes of Consolidative Surgery Following Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Cancer: A Real-World Experience
Alireza Ghoreifi, Christopher J Hoimes, Sundhar Ramalingam, et al.
Page
of 6